Results 181 to 190 of about 34,485 (247)

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes

open access: yesJournal of the American Geriatrics Society, Volume 74, Issue 1, Page 96-106, January 2026.
Effect of glucagon‐like peptide‐1 receptor agonist therapy on cardiorenal outcomes in patients aged ≥ 80 years with Type 2 diabetes. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however ...
Jui‐Cheng Chen   +4 more
wiley   +1 more source

Modulation of Master Transcription Factor Expression of Nile Tilapia Leukocytes via Cholinergic Pathways. [PDF]

open access: yesInt J Mol Sci
Girón-Pérez MI   +8 more
europepmc   +1 more source

Neurons in a Dish: A Review of In Vitro Cell Models for Studying Neurogenesis

open access: yesJournal of Neurochemistry, Volume 170, Issue 1, January 2026.
Different in vitro cell models are valuable to study the different steps of neurogenesis, from the proliferation of neural stem and progenitor cells to the maturation of neurons. Pluripotent stem cells (including embryonic stem cells and induced pluripotent stem cells), immortalized human neuroblastoma cell lines (SH‐SY5Y, IMR‐32), and primary brain ...
Mariana Vassal   +3 more
wiley   +1 more source

Selective α7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis [PDF]

open access: bronze, 2010
Susanne A. Snoek   +9 more
openalex   +1 more source

Nicotine Regulates LPS‐Induced Inflammatory Responses in HMC3 Microglia and Exerts Neuronal Protection

open access: yesMediators of Inflammation, Volume 2026, Issue 1, 2026.
Microglia‐mediated neuroimmune responses have been implicated in central nervous system injury and disease pathogenesis. The α7 nicotinic acetylcholine receptor (α7 nAChR), which is expressed on microglia and participates in microenvironment interactions, is a key mediator of the cholinergic anti‐inflammatory pathway.
Yuhan Qin   +9 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists Are Associated With Improved Outcomes in Inflammatory Bowel Disease

open access: yesGastroHep, Volume 2026, Issue 1, 2026.
Background The co‐existence of diabetes and obesity in patients with inflammatory bowel disease (IBD) increases morbidity and mortality associated with IBD, yet it remains unclear how medications used to treat these metabolic disorders affect IBD course.
Michael Saadeh   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy